Earnings Play HCA Healthcare
Look for a breakout from the symmetrical triangle pattern.
Share this:
On Monday, before market, HCA Healthcare (HCA) is anticipated to report third quarter EPS of $2.28 compared to $2.23 a year ago on revenue of approximately $13.0 billion vs. $12.7 billion last year. HCA Healthcare is one of the largest for-profit hospital operators in the U.S. and its current analyst consensus rating is 17 buys, 7 holds and 0 sells, according to Bloomberg.
Looking at a daily chart, HCA Healthcare's stock price appears to have formed a intermediate-term symmetrical triangle pattern that began to form in the early months of 2020. On a more short-term basis the company has been advancing in an uptrend since late September. Price is currently being stopped at the upper trendline of the symmetrical triangle and in the last 5 days of trading most of the candle sticks have formed short real bodies with long wicks hinting at indecision. The RSI is showing divergence as price made a slightly higher high in October than it did in early September and the RSI made a lower high. Price will likely begin a new short-term downtrend and head for 114.00. Price will probably find support at 114.00 and chop around before reaching for 101.00. On the other hand, if price can manage to get over 140.00 then it could retest the record high of roughly 152.00. If price gets above 152.00, then it could continue to rise.
Source: GAIN Capital, TradingView
Looking at a daily chart, HCA Healthcare's stock price appears to have formed a intermediate-term symmetrical triangle pattern that began to form in the early months of 2020. On a more short-term basis the company has been advancing in an uptrend since late September. Price is currently being stopped at the upper trendline of the symmetrical triangle and in the last 5 days of trading most of the candle sticks have formed short real bodies with long wicks hinting at indecision. The RSI is showing divergence as price made a slightly higher high in October than it did in early September and the RSI made a lower high. Price will likely begin a new short-term downtrend and head for 114.00. Price will probably find support at 114.00 and chop around before reaching for 101.00. On the other hand, if price can manage to get over 140.00 then it could retest the record high of roughly 152.00. If price gets above 152.00, then it could continue to rise.
Source: GAIN Capital, TradingView
On Monday, before market, HCA Healthcare (HCA) is anticipated to report third quarter EPS of $2.28 compared to $2.23 a year ago on revenue of approximately $13.0 billion vs. $12.7 billion last year. HCA Healthcare is one of the largest for-profit hospital operators in the U.S. and its current analyst consensus rating is 17 buys, 7 holds and 0 sells, according to Bloomberg.
Looking at a daily chart, HCA Healthcare's stock price appears to have formed a intermediate-term symmetrical triangle pattern that began to form in the early months of 2020. On a more short-term basis the company has been advancing in an uptrend since late September. Price is currently being stopped at the upper trendline of the symmetrical triangle and in the last 5 days of trading most of the candle sticks have formed short real bodies with long wicks hinting at indecision. The RSI is showing divergence as price made a slightly higher high in October than it did in early September and the RSI made a lower high. Price will likely begin a new short-term downtrend and head for 114.00. Price will probably find support at 114.00 and chop around before reaching for 101.00. On the other hand, if price can manage to get over 140.00 then it could retest the record high of roughly 152.00. If price gets above 152.00, then it could continue to rise.
Source: GAIN Capital, TradingView
Looking at a daily chart, HCA Healthcare's stock price appears to have formed a intermediate-term symmetrical triangle pattern that began to form in the early months of 2020. On a more short-term basis the company has been advancing in an uptrend since late September. Price is currently being stopped at the upper trendline of the symmetrical triangle and in the last 5 days of trading most of the candle sticks have formed short real bodies with long wicks hinting at indecision. The RSI is showing divergence as price made a slightly higher high in October than it did in early September and the RSI made a lower high. Price will likely begin a new short-term downtrend and head for 114.00. Price will probably find support at 114.00 and chop around before reaching for 101.00. On the other hand, if price can manage to get over 140.00 then it could retest the record high of roughly 152.00. If price gets above 152.00, then it could continue to rise.
Source: GAIN Capital, TradingView
Related tags:
Latest market news
The complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
S&P 500, Nasdaq, Dow Forecast: Wall Street Split Widens Into Month-End 9 26 2026
Nasdaq strength contrasts with mounting Dow pressure as rising Treasury yields raise the stakes for stocks heading into the monthly close.
USD/JPY Weekly Outlook: Payrolls loom as US rates remain the dominant driver
Strong US growth and hawkish Fed pricing continue to support USD/JPY, while intervention risk appears to be kicking in at lower levels
EUR/USD Q4 2026 Outlook: Euro at a Crossroads as Fed, ECB Tighten 9 25 2026
EUR/USD enters Q4 at a pivotal inflection point as competing Fed-ECB policy paths and persistent inflation risks collide with major technical support.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.